Phase 1, Open-Label, Randomized, 3-Way Crossover Relative Bioavailability of A4250 in Healthy Adult Subjects Under Fasting and Fed Conditions and When Sprinkled on Applesauce
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs Odevixibat (Primary)
- Indications Alagille syndrome; Intrahepatic cholestasis; Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Pruritus
- Focus Pharmacokinetics
- Sponsors Albireo Pharma
- 18 Sep 2018 Status changed from active, no longer recruiting to completed.
- 07 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Aug 2018 New trial record